Growth Hormone Therapy Medical Necessity Criteria: How Eligibility Is Determined

One of the most common questions parents ask after learning about growth treatment options is:

"How do doctors decide if growth hormone therapy is medically necessary?"

This is an important question because growth hormone therapy is not prescribed simply because a child is shorter than classmates or below average in height.

Instead, physicians use established growth hormone therapy medical necessity criteria to determine whether a child has a documented growth disorder, significant growth impairment, or another condition that may benefit from treatment.

Insurance companies also rely heavily on these criteria when deciding whether they will approve coverage.

Understanding how eligibility is determined helps parents know what to expect during a pediatric growth evaluation and why certain tests, measurements, and medical records are required before treatment can be considered.

What Does "Medical Necessity" Mean?

In pediatric endocrinology, medical necessity means there is objective evidence that treatment may provide meaningful medical benefit for a documented condition.

In other words, a physician must show that:

A growth problem exists
The growth problem has been properly evaluated
Treatment may improve growth outcomes
The expected benefits outweigh potential risks

Medical necessity standards help ensure children receive appropriate treatment while avoiding unnecessary interventions.

Why Growth Hormone Therapy Requires Strict Criteria

HGH for children to grow taller is a powerful medical treatment that often continues for several years.

Because therapy involves:

Daily or weekly injections
Ongoing monitoring
Regular physician follow-up
Significant financial investment

providers must carefully determine whether treatment is truly appropriate.

This is why most children undergo a comprehensive pediatric growth evaluation appointment before treatment discussions begin.

The First Requirement: Abnormal Growth Patterns

The most important factor in determining eligibility is whether a child's growth pattern is abnormal.

Doctors evaluate growth over time rather than relying on a single height measurement.

Height Alone Is Not Enough

Many healthy children are naturally shorter than average.

A child may be:

Short but healthy
A late bloomer
Following normal family growth patterns

Simply being short does not automatically justify growth hormone therapy.

Instead, physicians evaluate whether growth is progressing normally.

Height Significantly Below Expected Range

One of the most common criteria involves height percentile.

Children may undergo further evaluation when height falls significantly below age-based norms.

Providers compare:

Current height
Age-based growth charts
Sex-specific growth charts
Family height expectations

A child who is substantially shorter than expected based on parental height may require additional investigation.

This is particularly important when evaluating idiopathic short stature.

Poor Growth Velocity Is Often More Important Than Height

Many pediatric endocrinologists consider growth rate to be one of the most important indicators of a growth disorder.

This is referred to as:

poor growth velocity

Growth velocity measures how many inches or centimeters a child grows each year.

A child may have a normal height percentile but still qualify for further evaluation if yearly growth slows significantly.

Parents often begin investigating when they notice:

Growth slowing over time
Clothing sizes lasting longer than expected
Friends growing faster
Minimal yearly height gains

In many cases, slowed growth raises more concern than short stature itself.

Declining Growth Percentiles

Doctors also examine whether a child is maintaining their growth curve.

A child who consistently tracks along the 10th percentile may be completely healthy.

However, concern increases when a child begins crossing percentiles downward.

For example:

50th percentile to 25th percentile
25th percentile to 10th percentile
10th percentile to below the 3rd percentile

This pattern may indicate an underlying growth disorder.

Families often discover this while researching:

Bone Age Assessment Plays a Major Role

One of the most valuable tools used during growth evaluations is a bone age study.

A delayed bone age may indicate:

Additional growth potential remains
Development is occurring more slowly
A child may simply be a late bloomer

An advanced bone age may suggest:

Earlier growth plate closure
Reduced remaining growth time

A bone age assessment helps physicians determine whether treatment may still influence final adult height.

Hormone Testing and Laboratory Evaluation

Medical necessity criteria generally require objective testing.

Laboratory evaluation may include:

IGF-1 Testing

Low levels may suggest impaired growth hormone signaling.

Children with low IGF-1 often undergo further endocrine evaluation.

Growth Hormone Stimulation Testing

When appropriate, physicians may evaluate growth hormone production directly.

This helps determine whether a child has true growth hormone deficiency.

Thyroid Function Testing

Thyroid hormone plays a critical role in normal growth.

Hypothyroidism can sometimes mimic growth hormone disorders.

Additional Laboratory Studies

Testing may also evaluate:

Nutrition status
Chronic inflammation
Celiac disease
Other medical conditions affecting growth

Conditions Commonly Meeting Medical Necessity Criteria

While requirements vary, growth hormone therapy is most commonly considered medically necessary when a documented diagnosis exists.

Growth Hormone Deficiency

Among the clearest indications for treatment.

Children with confirmed growth hormone deficiency often experience:

Reduced growth velocity
Delayed growth progression
Lower IGF-1 levels

Idiopathic Short Stature

Some children with severe idiopathic short stature may qualify when specific guideline thresholds are met.

Pituitary Disorders

Children with pituitary disorders may have impaired hormone production affecting growth.

Certain Genetic Conditions

Several chromosomal and genetic syndromes may meet eligibility requirements.

Chronic Medical Conditions

Certain diseases that significantly impair growth may also qualify.

Constitutional Growth Delay and Delayed Puberty

Not every child who grows slowly requires growth hormone therapy.

Children with:

constitutional growth delay
delayed puberty

often continue growing later than peers.

These children may have:

Delayed bone age
Extended growth windows
Normal adult height potential

In many cases, monitoring rather than treatment is recommended.

This is one reason why a complete evaluation is so important.

How Insurance Companies Determine Medical Necessity

Insurance providers generally require extensive documentation before approving growth hormone therapy.

Requirements commonly include:

Growth Records

Historical height measurements demonstrating abnormal growth patterns.

Physician Documentation

Detailed clinical notes supporting medical necessity.

Bone Age Imaging

Evidence of skeletal maturity assessment.

Laboratory Results

Objective hormone testing results.

Diagnostic Confirmation

Documentation that other causes of slow growth have been evaluated.

Each insurance company uses slightly different criteria, but most follow similar pediatric endocrine guidelines.

Medical Necessity Does Not Automatically Mean Treatment

Even when a child qualifies medically, treatment remains an individualized decision.

Families and providers typically discuss:

Expected Benefits

How much growth improvement is realistically expected.

Remaining Growth Potential

How much time remains before growth plates close.

Treatment Commitment

The responsibilities associated with long-term therapy.

Cost Considerations

Many parents also evaluate:

before making a final decision.

Frequently Asked Questions

Does being short automatically qualify a child for HGH therapy?

No. Height alone is rarely enough. Physicians evaluate growth velocity, medical history, hormone testing, and other factors.

What is the most important eligibility factor?

Many specialists consider poor growth velocity one of the strongest indicators of a potential growth disorder.

Why is bone age important?

A bone age assessment helps estimate remaining growth potential and guides treatment decisions.

Can insurance deny growth hormone therapy?

Yes. Insurance companies often require detailed documentation demonstrating medical necessity.

What is the first step if parents are concerned?

Scheduling a child height specialist consultation or comprehensive growth evaluation is usually the best starting point.

The Bottom Line

Growth hormone therapy medical necessity criteria exist to ensure treatment is reserved for children with documented growth disorders, significant growth impairment, or conditions known to respond to therapy.

Doctors evaluate far more than height alone. Growth velocity, growth charts, bone age imaging, hormone testing, family history, and medical diagnoses all contribute to eligibility decisions.

Whether a child has growth hormone deficiency, idiopathic short stature, low IGF-1, pituitary disorders, or another growth-related condition, a thorough evaluation helps determine whether monitoring, further testing, or treatment is the most appropriate next step.

The earlier growth concerns are evaluated, the more opportunities families have to understand their child's growth potential and make informed decisions before growth plates close.

Medically Reviewed By

Dr. Devin Stone, ND

Dr. Devin Stone is a Doctor of Naturopathic Medicine and founder of HGHforChildren.com. His clinical focus includes pediatric growth optimization, growth hormone deficiency, delayed bone age assessment, constitutional growth delay, IGF-1 evaluation, and evidence-informed therapies designed to help children maximize healthy growth potential.

References

Pediatric Endocrine Society. Growth Hormone Deficiency Clinical Resources.
Growth Hormone Research Society Consensus Guidelines.
Endocrine Society Clinical Practice Guidelines for Growth Hormone Use.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Hormone Research in Paediatrics.
American Academy of Pediatrics. Growth Monitoring and Endocrine Disorders.
National Institutes of Health (NIH). Pediatric Growth Disorders.
Grimberg A, et al. Guidelines for Growth Hormone and IGF-1 Treatment in Children and Adolescents.

Dr. Devin Stone

Contact Me